Analysed PLIANT THERAPEUTICS INC (PLRX:NASDAQ) News Sources
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
18-04-2026
yahoo.com
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
18-03-2026
yahoo.com
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
11-03-2026
yahoo.com
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference
01-03-2026
marketbeat.com
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
23-02-2026
yahoo.com
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
04-12-2025
yahoo.com
Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation
18-11-2025
yahoo.com
What is the current price of PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?
The current price of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is $1.29.
PLIANT THERAPEUTICS INC (PLRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) since the previous trading day is $0.
PLIANT THERAPEUTICS INC (PLRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?
The most recent average sentiment score for PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?
The most recent sentiment for PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is .
SEC-8K** Filing Available For PLIANT THERAPEUTICS INC (PLRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.